Feds Launch $139 Million Project to Transform Addiction Treatment—And It Could Change How New Yorkers Get Care

For decades, treating addiction and serious mental illness has meant navigating a landscape of educated guesses. A patient tries one medication, then another. They switch therapists. They wait weeks or months to know if something is working—often while symptoms persist or worsen. The process is slow, expensive, and for many, demoralizing.

That could soon change.

On April 21, 2026, the Advanced Research Projects Agency for Health (ARPA-H)—the same federal agency tasked with driving high-risk, high-reward biomedical breakthroughs—announced the first wave of research teams for its most ambitious behavioral health initiative to date. The EVIDENT program (Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health) will invest up to $139.4 million to build something the field has never had: objective, measurable ways to know whether a treatment is working, and for whom.

The implications extend far beyond research labs. For New Yorkers seeking addiction treatment, the initiative could eventually mean faster access to effective therapies, fewer failed attempts, and care that is tailored to individual biology rather than trial and error.

---

The Problem EVIDENT Is Trying to Solve

Despite spending on behavioral health and substance use treatment more than tripling since 2000—from $40.9 billion annually to over $140 billion—the field still relies heavily on subjective assessments. Clinicians ask patients how they feel. Patients fill out questionnaires. These tools have value, but they are imprecise, delayed, and vulnerable to bias.

"For too long, we've dismissed treatments that could genuinely heal people—not because they don't work, but because medicine has never had the tools, and we've lacked the courage to prove it," said HHS Secretary Robert F. Kennedy Jr. in announcing the initiative.

The result is a system where promising therapies—especially newer approaches like psychedelic-assisted treatment, neuromodulation, and digital interventions—struggle to gain regulatory approval because there is no standardized way to demonstrate efficacy. Patients who might benefit are left without options, or forced to navigate unregulated underground markets.

ARPA-H Director Alicia Jackson put it more bluntly: "Today, mental health care too often depends on subjective scales, delayed feedback, and trial-and-error."

---

What EVIDENT Will Actually Build

The initiative is structured around four fundamental questions that researchers currently cannot answer reliably:

1. What should we use for objective measurement? (TA1)
2. What is happening during treatment? (TA2)
3. Who will respond to what treatment? (TA3)
4. What is our shared data foundation? (TA4)

The research teams announced this week—drawn from universities, biotech firms, and medical centers across the country—will attack these questions from multiple angles. Some will analyze biological markers like cortisol, interleukin, and other stress hormones found in saliva. Others will use multi-omics approaches (proteomics, genomics) to track physiological changes that correlate with mental health states. Wearable devices will feed continuous data into predictive models. Brain imaging and neuromodulation technologies will provide real-time windows into treatment effects.

Notable participants include Johns Hopkins University, which will contribute data from eight approved clinical trials on psilocybin; Duke University, quantifying stress biomarkers from saliva samples; and Yale's Stress Center, running trials on pregnenolone for alcohol use disorder. Several private companies are involved as well, including firms developing focused ultrasound for depression and platforms for real-time biomarker collection during psychedelic therapy.

At least $50 million of the total funding is specifically earmarked to match state government investments in psychedelic research for populations with serious mental illness—a provision that aligns with the Trump Administration's executive order on accelerating treatments for mental health conditions.

---

Why This Matters for New York

New York State has been at the forefront of expanding access to addiction treatment, from the proliferation of mobile medication units to the recent law requiring naloxone in workplace first aid kits. But even with expanded access, the underlying challenge remains: matching the right patient to the right treatment.

The EVIDENT initiative could provide tools to solve that problem. If successful, clinicians would have biomarker-based guidance on which patients are likely to respond to medication-assisted treatment versus psychotherapy, which might benefit from neuromodulation, or who could be candidates for emerging therapies like psilocybin-assisted treatment for alcohol use disorder.

For a state that saw overdose deaths drop by more than 30% in 2025—largely through harm reduction and expanded naloxone access—the next frontier is improving treatment effectiveness, not just availability. EVIDENT's objective measurement tools could help New York providers identify which interventions are working for specific patient populations, enabling faster course corrections and better outcomes.

The initiative also positions New York to potentially benefit from the $50 million in matching funds for state-level psychedelic research. While New York has not yet legalized psychedelic-assisted therapy, the EVIDENT data infrastructure could accelerate any future policy moves by providing the objective efficacy measures that regulators and insurers typically demand.

---

The Timeline and What Comes Next

ARPA-H has indicated that these initial awards are just the beginning. Additional research teams will be announced on a rolling basis as the initiative gathers momentum. The agency expects to integrate data from registered clinical trials and real-world care settings continuously, building what it calls "the first generation of scalable, objective measures of behavioral health."

The ultimate goal is ambitious: to enable providers to "move away from trial-and-error approaches" and toward "precise, personalized, data-driven care." For conditions like depression, anxiety, addiction, and PTSD, this could mean the difference between months of suffering and rapid, targeted relief.

But the timeline for real-world impact remains uncertain. While some biomarker tests could emerge within a few years, integrating them into standard clinical practice—especially in resource-constrained settings like community health centers and rural clinics—will take longer. Insurance coverage for biomarker-guided treatment decisions is another hurdle that will require separate policy advances.

Still, for a field that has seen relatively little technological disruption compared to other areas of medicine, the EVIDENT initiative represents a significant inflection point. The question is no longer whether objective measurement of behavioral health is possible, but how quickly the research can translate into clinical reality.

For New Yorkers struggling with addiction or mental illness—and for the providers trying to help them—that shift cannot come soon enough.